A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study

Docetaxel (75 mg m(−2) 3-weekly) is standard second-line treatment in advanced non-small-cell lung cancer (NSCLC) with significant toxicity. To verify whether a weekly schedule (33.3 mg m(−2) for 6 weeks) improved quality of life (QoL), a phase III study was performed with 220 advanced NSCLC patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Gridelli, C, Gallo, C, Di Maio, M, Barletta, E, Illiano, A, Maione, P, Salvagni, S, Piantedosi, F V, Palazzolo, G, Caffo, O, Ceribelli, A, Falcone, A, Mazzanti, P, Brancaccio, L, Capuano, M A, Isa, L, Barbera, S, Perrone, F
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409790/
https://www.ncbi.nlm.nih.gov/pubmed/15558071
http://dx.doi.org/10.1038/sj.bjc.6602241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409790/
https://www.ncbi.nlm.nih.gov/pubmed/15558071
http://dx.doi.org/10.1038/sj.bjc.6602241

Ejemplares similares